Infallible Pharma, a certified pharmaceutical company of Indian origin, has taken a big leap forward in providing injectable medication for critical infections. It has rolled out Merofin Meropenem Injection (Merofin), used in empirical monotherapy of serious bacterial infections in ICU patients.
Considered as a champion antibiotic against critical infections, Merofin by Infallible Pharma has higher rate of clinical success in primary or secondary lower respiratory tract infections and it’s also an efficient remedy for Nosocomial Infections and Febrile neutropenia. Equally useful in Septicemia that occurs when bacteria enter the bloodstream and spread, Merofin works by killing bacteria that cause infection.
Moreover, Merofin is a highly effective and well tolerated antibiotic used to treat a variety of bacterial meningitis. An intravenous (I.V.) bolus injection, Merofin comes as a powder to be mixed with liquid and injected intravenously. Merofin should be administered over 5 minutes, or through I.V. infusion over approximately 15-30 minutes with compatible infusion fluid for every 8-12 hours.
Hari Om, Chairman, Infallible Pharma Private Ltd said, “In the wake of challenge posed by COVID-19, it is vital to control all kinds of infections. While bacterial infections can cause serious life-threatening medical emergency, many high-risk bacterial infections can be treated effectively with the use of Merofin. We are proud of our ongoing commitment to the research and development of intravenous antibiotics and parenteral injectable therapy in critical care segment.”